COMMUNIQUÉS West-GlobeNewswire
-
Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026 -
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
24/02/2026 -
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026 -
AB Science annonce l'identification d'un biomarqueur plasmatique marqueur de l'activité du masitinib dans le traitement de la SLA
24/02/2026 -
Validic Adds Epic Toolbox, Generative AI, Multi-Instance Support, and More to Existing Epic Integration
24/02/2026 -
Empathy in Medicine Initiative Announces Student Chapter Program to Empower High School and College Students in Healthcare Leadership
24/02/2026 -
Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation
24/02/2026 -
Research in carrot and cherry crops to strengthen local food security
24/02/2026 -
EmblemHealth and Mae Health Announce Partnership to Give Members Access to Pregnancy and Postpartum Digital Health Support and Community-Based Doulas
24/02/2026 -
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
24/02/2026 -
Centre for Neuro Skills Physician-Researcher Dr. Brent Masel to Receive NABIS Legends Award for Lifetime of Contributions to Traumatic Brain Injury Care
24/02/2026 -
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
24/02/2026 -
Respiree Strengthens Series A Syndicate to Advance Next-Generation Cardiorespiratory Care
24/02/2026 -
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
24/02/2026 -
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24/02/2026 -
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
24/02/2026 -
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
24/02/2026 -
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026 -
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02/2026
Pages